Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)

Inclusion Criteria:

• Patient on treatment with octreotide LAR 20 mg administered every 28 days for at least 3 months prior to visit 1.
• Patient must have serum GH level ≤ 2.5 ng/mL and serum IGF-1 ≤ 1.3 ULN, 28 days after their last injection of octreotide LAR 20 mg at visit 1.
• Patients must have serum GH level > 2.5 ng/mL AND serum IGF-1 level > 1.3 ULN, 6 or 8 weeks after their last injection of octreotide LAR 20 mg.

Exclusion Criteria:

• The patient has received pituitary radiation therapy of any kind at any time prior to visit 1.
• The patient has received pituitary surgery within 3 months prior to visit 1.
• The patient's serum creatinine is higher than 150 µmol/l.